Literature DB >> 17322886

Alloreactive T cells respond specifically to multiple distinct peptide-MHC complexes.

Nathan J Felix1, David L Donermeyer, Stephen Horvath, James J Walters, Michael L Gross, Anish Suri, Paul M Allen.   

Abstract

The molecular basis underlying the specificity of alloreactive T cells for peptide-major histocompatibility complex ligands has been elusive. Here we describe a screen of 60 I-E(k)-alloreactive T cells and 83 naturally processed peptides that identified 9 reactive T cells. Three of the T cells responded to multiple, distinct peptides that shared no sequence homology. These T cells recognized each peptide-major histocompatibility complex ligand specifically and used a distinct constellation of I-E(k) contact residues for each interaction. Our studies show that alloreactive T cells have a 'germline-encoded' capacity to recognize multiple, distinct ligands and thus show 'polyspecificity', not degeneracy. Our findings help to explain the high frequency of alloreactive T cells and provide insight into the nature of T cell specificity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17322886     DOI: 10.1038/ni1446

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  68 in total

1.  Structural and energetic evidence for highly peptide-specific tumor antigen targeting via allo-MHC restriction.

Authors:  Amy A Simpson; Fiyaz Mohammed; Mahboob Salim; Amy Tranter; Alan B Rickinson; Hans J Stauss; Paul A H Moss; Neil M Steven; Benjamin E Willcox
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

Review 2.  T-cell activation and transplantation tolerance.

Authors:  Bhavana Priyadharshini; Dale L Greiner; Michael A Brehm
Journal:  Transplant Rev (Orlando)       Date:  2011-11-08       Impact factor: 3.943

3.  Ten experiments that would make a difference in understanding immune mechanisms.

Authors:  Melvin Cohn
Journal:  Cell Mol Life Sci       Date:  2011-11-01       Impact factor: 9.261

4.  Evolving concepts of specificity in immune reactions.

Authors:  Herman N Eisen; Arup K Chakraborty
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-20       Impact factor: 11.205

5.  Ewing sarcoma partial regression without GvHD by chondromodulin-I/HLA-A*02:01-specific allorestricted T cell receptor transgenic T cells.

Authors:  Uwe Thiel; Sebastian J Schober; Ingo Einspieler; Andreas Kirschner; Melanie Thiede; David Schirmer; Katja Gall; Franziska Blaeschke; Oxana Schmidt; Susanne Jabar; Andreas Ranft; Rebeca Alba Rubío; Uta Dirksen; Thomas G P Grunewald; Poul H Sorensen; Günther H S Richter; Irene Teichert von Lüttichau; Dirk H Busch; Stefan E G Burdach
Journal:  Oncoimmunology       Date:  2017-04-12       Impact factor: 8.110

6.  Low-Affinity Memory CD8+ T Cells Mediate Robust Heterologous Immunity.

Authors:  Scott M Krummey; Ryan J Martinez; Rakieb Andargachew; Danya Liu; Maylene Wagener; Jacob E Kohlmeier; Brian D Evavold; Christian P Larsen; Mandy L Ford
Journal:  J Immunol       Date:  2016-02-10       Impact factor: 5.422

Review 7.  An in depth analysis of the concept of "polyspecificity" assumed to characterize TCR/BCR recognition.

Authors:  Melvin Cohn
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 8.  Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers.

Authors:  Arnab Ghosh; Amanda M Holland; Marcel R M van den Brink
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

9.  Effect of CDR3 sequences and distal V gene residues in regulating TCR-MHC contacts and ligand specificity.

Authors:  Brian D Stadinski; Peter Trenh; Brian Duke; Priya G Huseby; Guoqi Li; Lawrence J Stern; Eric S Huseby
Journal:  J Immunol       Date:  2014-05-09       Impact factor: 5.422

10.  Human CD4(+) effector T lymphocytes generated upon TCR engagement with self-peptides respond defectively to IL-7 in their transition to memory cells.

Authors:  Gabriela González-Pérez; Norma C Segovia; Amaranta Rivas-Carvalho; Diana P Reyes; Honorio Torres-Aguilar; Sergio R Aguilar-Ruiz; Claudine Irles; Gloria Soldevila; Carmen Sánchez-Torres
Journal:  Cell Mol Immunol       Date:  2013-03-04       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.